This gynecologic malignancy is primarily a disease of postmenopausal females and generally denotes a good prognosis, as it is detected early due to its hallmark symptomatology – postmenopausal bleeding. Worldwide 188,000 new cases are diagnosed annually. Of all the uterine fundal cancers, endometrial carcinoma accounts for almost 90%, whereas leiomyosarcoma, endometrial stromal sarcoma, and mixed Mullerian tumors (carcinosarcoma) and others constitute the remaining 10%. The prime modality of treatment of endometrial carcinoma is surgery, the adjuvant treatments- radiotherapy, chemotherapy and hormone therapy have certain grey areas.